NewLink Genetics Corp. (NLNK) reported that its first-quarter of 2013 net loss widened to $7.9 million or $0.33 per share from $4.8 million or $0.23 per share in the first quarter of 2012.
Total grant revenues for the first quarter 2013 were $302,000 compared with $471,000 for the first quarter 2012.
Research and development expense for the first quarter 2013 was $6.3 million compared with $3.8 million for the first quarter 2012. The $2.5 million increase was primarily due to increased manufacturing and clinical trial expense from the same period in 2012.
General and administrative expense for the first quarter 2013 was $2.0 million compared with $1.5 million for the first quarter 2012. This increase was primarily due to increases in personnel related expenses.
The company said it expects to end 2013 with about $40 million in cash, cash equivalents and marketable securities.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.28 per share on revenues of $0.4 million for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.